The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback